Researchers for this study retrospectively looked at adverse events and lab changes in 284 patients with various neurological indications who received either plasma exchange or immunoadsorption. “Overall, both methods showed an excellent safety profile; no deaths of life-threatening adverse events were recorded,” the authors wrote. “Severe adverse events […] including three patients with sepsis, one pneumonia, and one pneumothorax were present in [five of] 435 immunoadsorption cycles (1.1%); in the plasma exchange group, no severe adverse events were recorded. Furthermore, although advantageous tolerability is generally considered the main advantage of immunoadsorption over plasma exchange, we found that overall frequency of adverse events (including grades 1 and 2) was higher in immunoadsorption (67.1% of all cycles) compared to plasma exchange (P<0.001).”